目的:探讨ATP结合盒亚家族C成员8(ABCC8)在不同类型胶质瘤中的表达情况及其与患者总生存期的关系。方法:收集中国胶质瘤基因组图谱(CGGA)数据库中516例胶质瘤患者的n ABCC8 mRNA数据及患者相应的临床特征[性别、年龄、组织病理类型、WHO分级、异柠檬酸脱氢酶(n IDH)突变状态、1p/19q缺失状态及分子病理分型]、总生存期等，比较不同类型胶质瘤患者间n ABCC8 mRNA的表达差异，以及不同类型胶质瘤患者中n ABCC8 mRNA高表达(≥54.50)与n ABCC8 mRNA低表达(<54.50)患者间总生存期的差异。n 结果:(1)原发性胶质瘤患者的n ABCC8 mRNA表达明显高于复发性患者，差异有统计学意义(n P<0.05)。少枝胶质细胞瘤患者的n ABCC8 mRNA表达最高，星形胶质细胞瘤患者次之，胶质母细胞瘤患者最低，不同组织病理类型胶质瘤患者间差异均有统计学意义(n P<0.05)。WHO Ⅱ级胶质瘤患者的n ABCC8 mRNA表达最高，WHO Ⅲ级患者次之，WHO Ⅳ级患者最低，不同WHO分级患者间差异均有统计学意义(n P<0.05)。n IDH突变型胶质瘤患者的n ABCC8 mRNA表达明显高于n IDH野生型患者，1p/19q缺失胶质瘤患者的n ABCC8 mRNA表达明显高于1p/19q不缺失患者，差异均有统计学意义(n P<0.05)。低级别胶质瘤患者及胶质瘤母细胞瘤患者中n IDH突变型患者的n ABCC8 mRNA表达均明显高于n IDH野生型患者，差异均有统计学意义(n P<0.05)。(2)在所有胶质瘤患者以及原发性、复发性胶质瘤，少枝胶质细胞瘤、星形胶质细胞瘤，WHO低级别(Ⅱ级)、WHO高级别(Ⅲ、Ⅳ级)胶质瘤，n IDH突变型、n IDH野生型胶质瘤，1p/19q缺失、1p/19q无缺失胶质瘤患者中，n ABCC8 mRNA高表达患者的总生存期均明显长于n ABCC8 mRNA低表达患者，差异均有统计学意义(n P<0.05)。(3)多因素Cox回归分析显示n ABCC8 mRNA表达是胶质瘤患者总生存期的独立影响因素(n HR=0.747，n P=0.025，n 95%CI：0.579~0.963)。n 结论:胶质瘤患者中n ABCC8 mRNA的表达与肿瘤恶性程度有关，且其可以作为预测患者预后的评估指标。n “,”Objective:To analyze the expression of ATP binding cassette subfamily C member 8 (ABCC8) in different types of gliomas and its relation with overall survival of glioma patients.Methods:The n ABCC8 mRNA data and clinical data (gender, age, histopathology, WHO grading, isocitrate dehydrogenase [n IDH] mutation status, 1p/19q deletion status and molecular types), and overall survival of 516 glioma patients from the Cancer Genome Atlas were collected, and the differences of n ABCC8 mRNA expression in different types of glioma patients were compared. The differences of overall survival were compared between high (≥54.50) and low (<54.50)n ABCC8 mRNA expression patients in different types of glioma patients.n Results:(1) n ABCC8 mRNA expression in primary glioma patients was significantly higher than that in recurrent glioma patients (n P<0.05).n ABCC8 mRNA expression was the highest in oligodendroglioma patients, followed by astrocytoma patients; and glioblastoma patients had the lowest n ABCC8 mRNA expression; the differences among glioma patients from subgroups of different histopathological types were statistically significant (n P<0.05).n ABCC8 mRNA expression was the highest in patients with grade II glioma, followed by those with grade III (n P<0.05); and patients with grade IV had the lowestn ABCC8 mRNA expression (n P<0.05); the differences among patients from subgroups of different WHO grading were statistically significant (n P<0.05).n ABCC8 mRNA expression in glioma patients with n IDH mutant was significantly higher than that in glioma patients with n IDH wild-type (n P<0.05); andn ABCC8 mRNA expression in patients with 1P/19Q deletion glioma was significantly higher than that in patients with 1P/19Q deletion (n P<0.05).n ABCC8 mRNA expression in low-grade glioma patients and glioblastoma multiforme patients with n IDH mutation was significantly higher than that in patients with n IDH wild-type (n P<0.05). (2) In all patients with glioma, primary and recurrent glioma, oligodendroglioma, neuroastrocytoma, WHO low-grading (grade II) and WHO high-grading (grade III or IV) glioma,n IDH mutation and n IDH wild-type gliomas, and 1p/19q deletion and no deletion gliomas, patients with high n ABCC8 mRNA expression had significantly higher overall survival time that those with low n ABCC8 mRNA expression (n P<0.05). (3) Multivariate Cox analysis showed thatn ABCC8 mRNA expression was an independent factor for overall survival of patients with gliomas (n HR=0.747, n P=0.025, n 95%CI:0.579-0.963).n Conclusion:The n ABCC8 mRNA expression in glioma patients is related to the malignant degrees of gliomas, which can be used as an indicator to predict the prognoses of gliomas.n